Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Buys $13,075.60 in Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCTGet Free Report) CEO Ron Bentsur purchased 1,940 shares of the business’s stock in a transaction dated Tuesday, May 14th. The shares were purchased at an average price of $6.74 per share, for a total transaction of $13,075.60. Following the acquisition, the chief executive officer now owns 3,246,424 shares of the company’s stock, valued at $21,880,897.76. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Ron Bentsur also recently made the following trade(s):

  • On Friday, May 10th, Ron Bentsur bought 2,000 shares of Nuvectis Pharma stock. The stock was acquired at an average cost of $6.40 per share, with a total value of $12,800.00.
  • On Monday, March 18th, Ron Bentsur purchased 5,000 shares of Nuvectis Pharma stock. The shares were acquired at an average cost of $10.29 per share, for a total transaction of $51,450.00.

Nuvectis Pharma Stock Down 5.8 %

NASDAQ:NVCT opened at $6.15 on Friday. The company has a 50 day simple moving average of $7.64 and a two-hundred day simple moving average of $8.10. Nuvectis Pharma, Inc. has a 12 month low of $5.92 and a 12 month high of $18.65.

Nuvectis Pharma (NASDAQ:NVCTGet Free Report) last posted its earnings results on Tuesday, March 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). As a group, equities analysts forecast that Nuvectis Pharma, Inc. will post -1.29 earnings per share for the current year.

Hedge Funds Weigh In On Nuvectis Pharma

A number of institutional investors and hedge funds have recently made changes to their positions in NVCT. Baldwin Brothers LLC MA grew its position in shares of Nuvectis Pharma by 22.0% during the 4th quarter. Baldwin Brothers LLC MA now owns 142,040 shares of the company’s stock valued at $1,185,000 after acquiring an additional 25,660 shares during the period. Strs Ohio raised its stake in shares of Nuvectis Pharma by 59.0% in the fourth quarter. Strs Ohio now owns 6,200 shares of the company’s stock worth $51,000 after buying an additional 2,300 shares during the period. Vanguard Group Inc. raised its stake in shares of Nuvectis Pharma by 1.5% in the first quarter. Vanguard Group Inc. now owns 298,800 shares of the company’s stock worth $2,450,000 after buying an additional 4,517 shares during the period. Blue Zone Wealth Advisors LLC bought a new position in shares of Nuvectis Pharma during the 1st quarter valued at approximately $118,000. Finally, Edmond DE Rothschild Holding S.A. purchased a new stake in Nuvectis Pharma in the 4th quarter worth approximately $160,000. Hedge funds and other institutional investors own 96.77% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $21.00 target price on shares of Nuvectis Pharma in a research note on Wednesday, May 8th.

View Our Latest Analysis on Nuvectis Pharma

About Nuvectis Pharma

(Get Free Report)

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.

Read More

Insider Buying and Selling by Quarter for Nuvectis Pharma (NASDAQ:NVCT)

Receive News & Ratings for Nuvectis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.